Viracta Therapeutics, Inc. (VIRX)
VIRX Stock Price Chart
Explore Viracta Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VIRX price movements and trends.
VIRX Company Profile
Discover essential business fundamentals and corporate details for Viracta Therapeutics, Inc. (VIRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Sept 2005
Employees
26.00
Website
https://www.viracta.comCEO
Craig R. Jalbert CIRA
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
VIRX Financial Timeline
Browse a chronological timeline of Viracta Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 28 Mar 2025
Earnings released on 13 Nov 2024
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%.
Earnings released on 14 Aug 2024
EPS came in at -$0.25 surpassing the estimated -$0.35 by +28.57%.
Earnings released on 9 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.35 by +34.29%.
Earnings released on 7 Mar 2024
EPS came in at -$0.35 falling short of the estimated -$0.30 by -16.67%, while revenue for the quarter reached $738.00K .
Earnings released on 9 Nov 2023
EPS came in at -$0.33 matching the estimated -$0.33.
Earnings released on 14 Aug 2023
EPS came in at -$0.32 falling short of the estimated -$0.30 by -6.67%.
Earnings released on 8 May 2023
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%.
Earnings released on 13 Mar 2023
EPS came in at -$0.27 surpassing the estimated -$0.40 by +32.50%.
Earnings released on 10 Nov 2022
EPS came in at -$0.47 falling short of the estimated -$0.31 by -51.61%.
Earnings released on 9 Aug 2022
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%.
Earnings released on 10 May 2022
EPS came in at -$0.28 surpassing the estimated -$0.32 by +12.50%.
Earnings released on 16 Mar 2022
EPS came in at -$0.31 surpassing the estimated -$0.47 by +34.04%.
Earnings released on 10 Nov 2021
EPS came in at -$0.40 falling short of the estimated -$0.31 by -29.03%.
Earnings released on 12 Aug 2021
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 12 May 2021
EPS came in at $0.38 surpassing the estimated $0.10 by +266.80%.
Stock split effective on 25 Feb 2021
Shares were split 57 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 24 Feb 2021
EPS came in at -$0.73 surpassing the estimated -$0.96 by +23.96%.
Earnings released on 16 Nov 2020
EPS came in at -$1.01 surpassing the estimated -$1.18 by +14.41%.
VIRX Stock Performance
Access detailed VIRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.